Medication Fact Sheets
|
August 15, 2025

Pravastatin: Uses, Side Effects, and Dosage Guide

Medically Reviewed by
Updated On
August 25, 2025

Heart disease remains the leading cause of death worldwide. Managing cholesterol levels is a critical step in preventing heart attacks and strokes.

Pravastatin (Pravachol®), a widely prescribed statin, helps lower low-density lipoprotein cholesterol (LDL-C) and reduce the risk of cardiovascular events. Whether you're newly diagnosed or exploring treatment options, pravastatin could be one option in your toolkit to help get your cholesterol under control.

This guide explains the benefits, side effects, dosage, and comparisons of pravastatin to help you and your healthcare provider make informed choices.

[signup]

What Is Pravastatin?

Pravastatin is a medication belonging to a class of drugs called statins, which are used to lower cholesterol levels in the blood. 

Statins work by blocking an enzyme in the liver (HMG CoA reductase) that catalyzes the rate-limiting step in cholesterol production. By blocking this enzyme, statins reduce the amount of cholesterol the body makes and the total amount of cholesterol in circulation. 

Pravastatin is classified as a hydrophilic statin, meaning it is water-soluble. This characteristic affects how the drug is absorbed and processed in the body compared to lipophilic statins (e.g., atorvastatin), which are fat-soluble. Hydrophilic statins may result in a lesser cholesterol reduction but may also be less likely to cause side effects than lipophilic statins.

Positive lipid outcomes associated with pravastatin include:

  • Reductions in lipid markers associated with arterial plaque deposition and atherosclerosis: total cholesterol (TC), LDL-C, very-low-density lipoprotein (VLDL), triglycerides (TG), and apolipoprotein B (ApoB)
  • Increases in high-density lipoprotein cholesterol (HDL-C, "good cholesterol")

Uses of Pravastatin

Pravastatin is approved by the U.S. Food and Drug Administration (FDA) as an adjunctive therapy to diet to:

The American Heart Association (AHA) and the American College of Cardiology (ACC) provide comprehensive guidelines for managing blood cholesterol. According to the 2018 AHA/ACC guidelines, statin therapy is recommended for the following groups: 

  • Patients with clinical atherosclerotic cardiovascular disease (ASCVD)
  • Patients with LDL-C > 190 mg/dL
  • Patients ages 40-75 with diabetes mellitus and LDL-C > 70 mg/dL
  • Adults ages 40-75 without diabetes mellitus and LDL-C > 70 mg/dL at a 10-year ASCVD risk of > 7.5%

Dosage and Administration

Pravastatin is considered a low-to-moderate-intensity statin, depending on its dose. General dosage guidelines are outlined below. Because dose can differ between two people based on individual factors, always follow your doctor's instructions when taking pravastatin or any other statin medication.

Dosage Forms

Pravastatin comes in 10 mg, 20 mg, 40 mg, and 80 mg tablets.

Dosage and Administration

The recommended dosage guidelines for pravastatin are as follows:

  • Adults: Start with 40 mg once daily; increase to 80 mg if patients do not reach LDL-C goal. 
  • Adolescents (Ages 14-18 Years): Start with 40 mg once daily; doses greater than 40 mg have not been studied in this population.
  • Children (Ages 8-13 Years): Start with 20 mg once daily; doses greater than 20 mg have not been studied in this population.
  • Dosage Modifications: The recommended starting dose is 10 mg once daily for patients with significant kidney impairment. 

Patients should follow a cholesterol-lowering diet while taking pravastatin. 

Pravastatin can be administered by mouth as a single dose at any time of day, with or without food. If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose; do not take extra or double doses.

Pravastatin Side Effects

In clinical trials, the most commonly reported side effects of pravastatin include:

  • Musculoskeletal pain
  • Nausea and vomiting
  • Upper respiratory infection
  • Diarrhea 
  • Headache

Other common side effects may include: 

  • Dizziness
  • Constipation
  • Abdominal pain
  • Indigestion and heartburn
  • Flushing
  • Insomnia
  • Urinary tract infection 
  • Fatigue
  • Itching
  • Rash
  • Cough

Potentially serious side effects that require dosage adjustments include: 

  • Chest pain
  • Edema (swelling) 
  • Hepatitis (liver inflammation)
  • Rhabdomyolysis (excessive muscle breakdown with secondary kidney failure)
  • Hyperglycemia (high blood sugar)
  • Blurred vision
  • Confusion

Managing Reactions

To prevent and manage side effects, patients should undergo a comprehensive health evaluation to screen for any contraindications to therapy and risk factors for side effects. This should include:

  • Current medications and supplements
  • Kidney function
  • Liver health
  • Blood sugar
  • Lipid levels

After starting treatment, patients should talk to their doctor if they experience any symptoms of serious side effects, including:

  • Muscle pain or weakness
  • Unexplained fatigue
  • Dark-colored urine
  • Yellowing of the skin or eyes

Statin-induced muscle pain affects up to 25% of people on statin therapy, leading to dosage reduction and discontinuation. Supplemental coenzyme Q10 (CoQ10) and vitamin D have been shown to be effective strategies for managing statin-induced muscle symptoms and improving medication adherence.

Warnings and Precautions

Pravastatin is contraindicated in the following scenarios:

  • Known allergy to any component of the medication
  • Active liver disease or unexplained, persistent elevations of liver enzymes
  • Pregnancy and breastfeeding

Taking pravastatin with certain medicines can interfere with how the medications work or increase the risk of severe side effects. The following considerations should be taken to reduce the risk of drug interactions

  • Bile acid sequestrants (e.g, cholestyramine) can impair pravastatin's absorption. When taking these medications together, administer pravastatin one hour before or at least four hours after the bile-acid binder.
  • Immunosuppressive medications (e.g., cyclosporine) increase the risk of rhabdomyolysis when taken with pravastatin. Patients on immunosuppressive medications should begin with 10 mg of pravastatin at bedtime. Titration to higher doses should be done carefully; most patients do not receive more than 20 mg of pravastatin daily. 
  • Macrolide antibiotics (e.g., clarithromycin) increase the risk of rhabdomyolysis. Patients taking clarithromycin or other macrolides should not take more than 40 mg of pravastatin daily. 
  • Colchicine increases the risk of rhabdomyolysis. 
  • Fibrates are another class of medication that lowers cholesterol levels. Fibrates (e.g., gemfibrozil) are usually avoided with statins because they can inhibit statin metabolism and increase the risk of rhabdomyolysis. 
  • Niacin (vitamin B3) has been shown to reduce VLDL and increase HDL-C levels. However, when niacin is administered with statin therapy, there is an increased risk for muscle-associated side effects. Consider reducing the dose of pravastatin with this therapeutic combination. 

Alcohol may offset some of the cardioprotective benefits of taking a statin— it is associated with higher LDL-C, TG, and blood pressure. Additionally, alcohol can increase the risk of statin-associated muscle symptoms and liver injury. Therefore, it is generally recommended to limit alcohol consumption while taking pravastatin. 

Pravastatin vs. Other Statins

Depending on its dosage, pravastatin is considered a low-to-moderate-intensity statin.

  • Pravastatin 10-20 mg is a low-intensity statin that can lower LDL-C levels by 20-25%.
  • Pravastatin 40-80 mg is a moderate-intensity statin that can lower LDL-C levels by 30-49%.

Pravastatin at doses of 40-80 mg reduces LDL-C less than high-intensity statins like atorvastatin and rosuvastatin, which can lower LDL-C by > 50%. 

Studies confirm that pravastatin effectively lowers LDL-C, TC, and TG, but its LDL-C-lowering effect is less pronounced than high-intensity statin medications.

  • A systematic review found that pravastatin 10-80 mg/day reduces LDL-C by 21.7-31.9%, TC by 16.1-23.3%, and TG by 5.8-20%, less than what atorvastatin and rosuvastatin can achieve. 
  • The STELLAR trial demonstrated that rosuvastatin 10-80 mg/day reduces LDL-C by 26% more on average than pravastatin 10-40 mg/day.

Pravastatin's increased tolerability is an advantage over other statin medications. Because of its hydrophilic nature, it is generally less likely to cause muscle-related adverse effects compared to other statins, particularly those metabolized by the cytochrome P450 system, such as atorvastatin and simvastatin.

It is standard practice to remeasure lipid panels 4-12 weeks after initiating or modifying statin therapy to track treatment efficacy, with dosage increases as needed to meet therapeutic targets. If pravastatin 80 mg (or the maximum-tolerated dose) does not sufficiently lower LDL-C levels, your healthcare provider may recommend switching to another statin.

Frequently Asked Questions (FAQs)

What are the worst side effects of pravastatin?

Severe adverse effects of statin medications are very rare but include rhabdomyolysis, acute kidney failure, and liver damage.

What is the best statin with the least side effects?

A meta-analysis of randomized controlled trials found pravastatin and simvastatin to be safer and more tolerable than other statin medications.

What should I avoid when taking pravastatin?

Avoid excessive alcohol consumption, and be cautious with other medications that may interact with pravastatin, such as niacin and gemfibrozil.

Should pravastatin be taken in the morning or at night?

Pravastatin can be taken either in the morning or at night; however, there is a slight preference for evening administration because the body produces more cholesterol during the night

[signup]

Key Takeaways

  • Pravastatin is a low-to-moderate-intensity cholesterol-lowering medication with a favorable safety profile. 
  • When used appropriately under the guidance of a healthcare provider, it is one of several medications available to help manage cholesterol and improve cardiovascular health.
  • If you're considering or already taking pravastatin, be informed and proactive about your care plan. For more information, explore our related articles on heart health and cholesterol management, and ask your doctor about the best cholesterol treatment options for you.
The information in this article is designed for educational purposes only and is not intended to be a substitute for informed medical advice or care. This information should not be used to diagnose or treat any health problems or illnesses without consulting a doctor. Consult with a health care practitioner before relying on any information in this article or on this website.

Learn more

No items found.

Lab Tests in This Article

No lab tests!
  1. Adams, S. P., Alaeiilkhchi, N., Tasnim, S., et al. (2023). Pravastatin for lowering lipids. The Cochrane Library, 2023(9), CD013673. https://doi.org/10.1002/14651858.cd013673.pub2
  2. Anderson, S. (2022, May 19). 6 Preventable Risk Factors Associated With Heart Attacks. Rupa Health. https://www.rupahealth.com/post/5-things-to-do-after-a-heart-attack
  3. Bryant, A. (2024, January 31). How to Lower Blood Cholesterol Levels: Natural and Pharmacologic Options. Rupa Health. https://www.rupahealth.com/post/how-to-lower-blood-cholesterol-levels-natural-and-pharmacologic-options
  4. Chong, P. H., Seeger, J. D., & Franklin, C. (2001). Clinically relevant differences between the statins: implications for therapeutic selection. The American Journal of Medicine, 111(5), 390–400. https://doi.org/10.1016/s0002-9343(01)00870-1
  5. Climent, E., Benaiges, D., & Pedro-Botet, J. (2021). Hydrophilic or Lipophilic Statins? Frontiers in Cardiovascular Medicine, 8, 687585. https://doi.org/10.3389/fcvm.2021.687585
  6. Cloyd, J. (2022, October 4). 4 nutrition hacks that lower high cholesterol. Rupa Health. https://www.rupahealth.com/post/4-nutrition-hacks-to-lower-high-cholesterol
  7. Cloyd, J. (2023, April 7). Functional medicine high cholesterol protocol. Rupa Health. https://www.rupahealth.com/post/functional-medicine-high-cholesterol-protocol
  8. Cloyd, J. (2023, May 1). A Functional Medicine Protocol for Coronary Artery Disease. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-protocol-for-coronary-artery-disease
  9. Cloyd, J. (2024, March 1). What is Hyperlipidemia? Symptoms, Testing, and Treatments. Rupa Health. https://www.rupahealth.com/post/what-is-hyperlipidemia-symptoms-testing-and-treatments
  10. Cloyd, J. (2024, March 4). The Role of Statins in Managing High Cholesterol: Benefits and Side Effects. Rupa Health. https://www.rupahealth.com/post/the-role-of-statins-in-managing-high-cholesterol-benefits-and-side-effects
  11. Cloyd, J. (2024, March 5). How to lower LDL cholesterol naturally: Evidence-Based recommendations. Rupa Health. https://www.rupahealth.com/post/how-to-lower-ldl-cholesterol-naturally-evidence-based-recommendations
  12. Cloyd, J. (2024, March 13). The Genetic Basis of Familial Hypercholesterolemia and Its Clinical Implications. Rupa Health. https://www.rupahealth.com/post/the-genetic-basis-of-familial-hypercholesterolemia-and-its-clinical-implications
  13. Cloyd, J. (2024, September 12). High-Intensity Statins: A Guide for Optimal Heart Health. Rupa Health. https://www.rupahealth.com/post/high-intensity-statins-a-guide-for-optimal-heart-health
  14. Cloyd, J. (2024, September 16). Understanding High Triglycerides: Causes, Symptoms, and Effective Management. Rupa Health. https://www.rupahealth.com/post/understanding-high-triglycerides-causes-symptoms-and-effective-management
  15. Cloyd, J. (2025, April 4). Colchicine: Uses, Benefits, and Side Effects Explained. Rupa Health. https://www.rupahealth.com/post/colchicine-uses-benefits-and-side-effects-explained
  16. Di Cesare, M., Perel, P., Taylor, S., et al. (2024). The Heart of the World. Global Heart, 19(1), 11. https://doi.org/10.5334/gh.1288
  17. Feingold, K. R. (2022). Guidelines for the management of high blood cholesterol. In K. R. Feingold, B. Anawalt, A. Boyce, et al. (Eds.), PubMed. MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK305897/
  18. Foglesong Stabile, J. (2024, November 27). Rosuvastatin: Benefits, Side Effects, and Key Considerations for Patients and Healthcare Professionals. Rupa Health. https://www.rupahealth.com/post/rosuvastatin-benefits-side-effects-and-key-considerations-for-patients-and-healthcare-professionals
  19. Garrison, K. (2024, July 12). CoQ10 and Statins: Why Take Them Together. Rupa Health. https://www.rupahealth.com/post/coq10-and-statins
  20. Grundy, S. M., Stone, N. J., Bailey, A. L., et al. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation, 139(25), e1082–e1143. https://doi.org/10.1161/cir.0000000000000625
  21. HIGHLIGHTS OF PRESCRIBING INFORMATION. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019898s062lbl.pdf
  22. Horne, B. D., Le, V. T., May, H. T., et al. (2022). Abstract 11652: What is the Relative Risk for Elevated Liver Function Tests of Single and Combined Statin and Alcohol Use and Implications for Management? Circulation, 146(Suppl_1). https://doi.org/10.1161/circ.146.suppl_1.11652
  23. How to Spot the Top Warning Signs of a Stroke. (2024, May 17). Rupa Health. https://www.rupahealth.com/post/how-to-spot-the-top-warning-signs-of-a-stroke
  24. Jones, P. H., Davidson, M. H., Stein, E. A., et al. (2003). Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). The American Journal of Cardiology, 92(2), 152–160. https://doi.org/10.1016/s0002-9149(03)00530-7
  25. Kofink, D., Eppinga, R. N., van Gilst, W. H., et al. (2017). Statin Effects on Metabolic Profiles. Circulation: Cardiovascular Genetics, 10(6), e001759. https://doi.org/10.1161/circgenetics.117.001759
  26. Michos, E. D., McEvoy, J. W., & Blumenthal, R. S. (2019). Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease. New England Journal of Medicine, 381(16), 1557–1567. https://doi.org/10.1056/nejmra1806939
  27. Naci, H., Brugts, J., & Ades, T. (2013). Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246,955 participants from 135 randomized, controlled trials. Circulation: Cardiovascular Quality and Outcomes, 6(4), 390–399. https://doi.org/10.1161/circoutcomes.111.000071
  28. Pravastatin. Cleveland Clinic. https://my.clevelandclinic.org/health/drugs/19928-pravastatin-tablets
  29. Qu, H., Guo, M., Chai, H., et al. (2018). Effects of Coenzyme Q10 on Statin‐Induced Myopathy: An Updated Meta‐Analysis of Randomized Controlled Trials. Journal of the American Heart Association, 7(19), e009835. https://doi.org/10.1161/jaha.118.009835
  30. Reston, J. T., Buelt, A., Donahue, M. P., et al. (2020). Interventions to Improve Statin Tolerance and Adherence in Patients at Risk for Cardiovascular Disease. Annals of Internal Medicine, 173(10), 806–812. https://doi.org/10.7326/m20-4680
  31. Robinson, K. (2025, January 6). Immunosuppressants: A Comprehensive Guide. Rupa Health. https://www.rupahealth.com/post/immunosuppressants-a-comprehensive-guide
  32. Sasaki, J., Otonari, T., Uchida, Y., et al. (2013). Effects of Pravastatin and Atorvastatin on HDL Cholesterol and Glucose Metabolism in Patients with Dyslipidemia and Glucose Intolerance: The PRAT Study. Journal of Atherosclerosis and Thrombosis, 20(4), 368–379. https://doi.org/10.5551/jat.13532
  33. Schroor, M. M., Sennels, H. P., Fahrenkrug, J., et al. (2019). Diurnal Variation of Markers for Cholesterol Synthesis, Cholesterol Absorption, and Bile Acid Synthesis: A Systematic Review and the Bispebjerg Study of Diurnal Variations. Nutrients, 11(7), 1439. https://doi.org/10.3390/nu11071439
  34. Sidhu, G., & Sapra, A. (2020). Pravastatin. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK551621/
  35. Singh, G., & Correa, R. (2020). Fibrate Medications. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK547756/
  36. Suzuki, T., Fukui, S., Shinozaki, T., et al. (2025). Lipid Profiles After Changes in Alcohol Consumption Among Adults Undergoing Annual Checkups. JAMA Network Open, 8(3), e250583. https://doi.org/10.1001/jamanetworkopen.2025.0583
  37. Triscari, J., Rossi, L., & Pan, H. Y. (1995). Chronokinetics of Pravastatin Administered in the PM Compared with AM Dosing. American Journal of Therapeutics, 2(4), 265–268. https://doi.org/10.1097/00045391-199504000-00008
  38. Warden, B. A., Guyton, J. R., Kovacs, A. C., et al. (2022). Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association. Journal of Clinical Lipidology, 17(1), 19–39. https://doi.org/10.1016/j.jacl.2022.09.001
  39. Yoshimura, H. (2024, February 29). Testing and Managing Mixed Hyperlipidemia: Challenges and Opportunities. Rupa Health. https://www.rupahealth.com/post/testing-and-managing-mixed-hyperlipidemia-challenges-and-opportunities
Order from 30+ labs in 20 seconds (DUTCH, Mosaic, Genova & More!)
We make ordering quick and painless — and best of all, it's free for practitioners.

Latest Articles

View more on Medication Fact Sheets
Subscribe to the magazine for expert-written articles straight to your inbox
Join the thousands of savvy readers who get root cause medicine articles written by doctors in their inbox every week!
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.

Hey practitioners! 👋 Join Dr. Amber Sereda, ND for an insightful webinar, "Bile Acid Insights with GI-MAP & StoolOMX," on Wednesday, September 17 at 11:00 AM PT / 2:00 PM EST.

In this session, you’ll explore how GI-MAP and StoolOMX testing may offer insights into bile acid-related patterns, how shifts in primary and secondary bile acids might be reflected in lab results, and practical considerations for interpreting these findings in a wellness-focused context.

Register now to secure your spot!